Roka Bioscience (ROKA) Tops Q4 EPS by 9c

Roka Bioscience (NASDAQ: ROKA) reported Q4 EPS of ($0.43), $0.09 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.36 million versus the consensus estimate of $1.44 million.

For earnings history and earnings-related data on Roka Bioscience (ROKA) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Is the global equity rally broadening? UBS weighs in
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results